Position statement of the Australian diabetes society: Individualisation of glycated haemoglobin targets for adults with diabetes mellitus

Medical Journal of Australia

Volumn 191, Issue 6, 2009, Pages 339-344

  Wah Cheung, N ^a,b   Conn, Jennifer J ^c   D'Emden, Michael C ^d   Gunton, Jenny E ^a,b,e   Jenkins, Alicia J ^f   Ross, Glynis P ^g,h   Sinha, Ashim K ⁱ   Andrikopoulos, Sofianos ^f   Colagiuri, Stephen ^b   Twigg, Stephen M ^b,g  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

ⁱ CAIRNS BASE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; HEMOGLOBIN A1C; LIPID;

BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SOCIETY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREGNANCY; REVIEW; SMOKING CESSATION;

EID: 77952310384     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02819.x     Document Type: Review

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Turner RC, Holman RR, Cull CA, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Turner RC, Holman RR, Stratton IM, et al. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Colagiuri S, Dickinson S, Girgis S, Colagiuri R. Evidence based guideline for blood glucose control in type 2 diabetes. Public consultation draft, August 2008. http://www.diabetesaustralia.com.au/PageFiles/7852/ FINALBLOODGLUCOSEpublicconsultationdocumentAugust2008.pdf (accessed Aug 2009).
5. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559. (Pubitemid 351831356)
6. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. (Pubitemid 351831357)
7. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
8. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
9. 1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-420.
10. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431.
11. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412. (Pubitemid 30609442)
12. Wright AD, Cull CA, Macleod KM, Holman RR. Hypoglycaemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006; 20: 395-401.
13. White NH, Sun W, Cleary PA, et al. Prolonged effect of intensive therapy in the risk of retinopathy complications in patients with type 1 diabetes mellitus. Arch Ophthalmol 2008; 126: 1707-1715.
14. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study. JAMA 2003; 290: 2159-2167.
15. Martin CL, Waberski B, Albers J, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340-344. (Pubitemid 44106515)
16. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653. (Pubitemid 41817713)
17. Guerin A, Nisenbaum R, Rav JG. Use of maternal GHb concentration to estimate the risk of congenital anomaly in the offspring of women with prepregnancy diabetes. Diabetes Care 2007; 30: 1920-1925. (Pubitemid 47036383)
18. Clausen TD, Mathiesen E, Ekbom P, et al. Poor pregnancy outcome in women with type 2 diabetes. Diabetes Care 2005; 28: 323-328. (Pubitemid 40170934)
19. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996; 174: 1343-1353.
20. McElduff A, Cheung NW, McIntyre HD, et al. The Australasian Diabetes in Pregnancy Society consensus guidelines for the management of type 1 and type 2 diabetes in relation to pregnancy. Med J Aust 2005; 183: 373-377. (Pubitemid 41430840)
21. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes - STENO 2. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
22. Turner R, Holman R, Stratton I, et al. Tight blood-pressure control and risk of macrovascular and microvascular complications in patients with type 2 diabetes: (UKPDS 38). Lancet 1998; 352: 837-853. (Pubitemid 28414300)
23. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. (Pubitemid 47362321)
24. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22. (Pubitemid 34756487)
26. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762. (Pubitemid 28269185)